Vivus Falls after Downgrade
August 17, 2012 at 15:36 PM EDT
Vivus (VVUS) shares are down 4.3% this afternoon after an analyst questioned the company’s ability to fight off generic competition for its new obesity drug Qsymia. Jefferies analyst Thomas Wei writes that doctors may decide to prescribe two generic drugs that make up the Vivus drug, instead of giving them the drug itself. He downgraded [...]
